CA2736406C — Compositions comprising diethanolamine salts of trepostinil in the treatment of pulmonary hypertension and other cardiovascular diseases
Assigned to United Therapeutics Corp · Expires 2014-11-18 · 11y expired
What this patent protects
A therapeutic composition is described. The composition may include a diethanolamine salt of treprostinil in combination with at least one additional cardiovascular agent selected from the group consisting of a calcium channel blocker, a phosphodiesterase inhibitor, and an endoth…
USPTO Abstract
A therapeutic composition is described. The composition may include a diethanolamine salt of treprostinil in combination with at least one additional cardiovascular agent selected from the group consisting of a calcium channel blocker, a phosphodiesterase inhibitor, and an endothelin receptor antagonist. The composition demonstrates a benefit in combination with other cardiovascular agents.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.